A Study to Assess the Effects of ACI-24.060
Phase 1/2
176
about 4 years
35–85
7 sites in AZ, IN, KS +4
About this study
This trial is testing a treatment called ACI-24.060 in people with prodromal Alzheimer's disease and adults with Down syndrome who don't have dementia yet. The goal is to see if this treatment is safe, well-tolerated, causes any immune reactions, and how it affects the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive ACI-24.060 at Dose A
- 2.Receive ACI-24.060 at Dose B
- 3.Receive ACI-24.060 at Dose C
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change from baseline in Anti-Abeta antibody titers in blood, Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related), Number of participants with abnormal MRI results
Secondary: Change from baseline in Anti-Abeta antibody titers, Change from baseline on brain amyloid levels
Neurology